CoChat

For avid glucose tumors, the SUV peak is the most reliable parameter for [18F]FDG-PET/CT quantification, regardless of acquisition time

Open access
Sher, Avigaëlle, Lacoeuille, Franck, Fosse, Pacôme, Vervueren, Laurent, Cahouet-Vannier, Aurélie, Dabli, Djamel, Bouchet, Francis, Couturier, Olivier · 2016 · EJNMMI Research

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

BACKGROUND: This study is an assessment of the impact of acquisition times on SUV with [(18)F]FDG-PET/CT on healthy livers (reference organ with stable uptake over time) and on tumors. METHODS: One hundred six [(18)F]FDG-PET/CT were acquired in list mode over a single-bed position (livers (n = 48) or on tumors (n = 58)). Six independent datasets of different durations were reconstructed (from 1.5 to 10 min). SUVmax (hottest voxel), SUVpeak (maximum average SUV within a 1-cm(3) spherical volume), and SUVaverage were measured within a 3-cm-diameter volume of interest (VOI) in the right lobe of the liver. For [(18)F]FDG avid tumors (SUVmax ≥ 5), the SUVmax, SUVpeak, and SUV41% (isocontour threshold method) were computed. RESULTS: For tumors, SUVpeak values did not vary with acquisition time. SUVmax displayed significant differences between 1.5- and 5-10-min reconstruction times. SUV41% was the most time-dependent parameter. For the liver, the SUVaverage was the sole parameter that did not vary over time. CONCLUSIONS: For [(18)F]FDG avid tumors, with short acquisition times, i.e., with new generations of PET systems, the SUVpeak may be more robust than the SUVmax. The SUVaverage over a 3-cm-diameter VOI in the right lobe of the liver appears to be a good method for a robust and reproducible assessment of the hepatic metabolism.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13550-016-0177-8

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 111

Metadata

Authors
Sher, A., Lacoeuille, F., Fosse, P., Vervueren, L., Cahouet-Vannier, A., Dabli, D., Bouchet, F., & Couturier, O.
Affiliations
  • Centre Hospitalier Universitaire d'Angers (FR)
  • Inserm (FR)
Corresponding author
Sher, Avigaëlle
Venue
EJNMMI Research
Published
2016-03-05
Volume
6
Issue
1
Pages
21-21
ISSN
2191-219X (ISSN-L)
OpenAlex
W2292171573
Cited by
111
References
24
Citations by year
2026: 6 · 2025: 5 · 2024: 13 · 2023: 23 · 2022: 15 · 2021: 16 · 2020: 8 · 2019: 12 · 2018: 6 · 2017: 5 · 2016: 1
FWCI
6.94
Type
journal article
Language
en
Open access
Locations
  • EJNMMI Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
Keywords
18F-FDG PET/CT, SUVpeak, SUVmax, acquisition time, list-mode acquisition, liver SUV, tumor quantification, hepatic glucose metabolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: For avid glucose tumors, the SUV peak is the most reliable parameter for [18F]FDG-PET/CT quantification, regardless of acquisition time. https://app.cochat.ai/papers/10.1186/s13550-016-0177-8
The paper
Sher, A., Lacoeuille, F., Fosse, P., Vervueren, L., Cahouet-Vannier, A., Dabli, D., Bouchet, F., & Couturier, O. (2016). For avid glucose tumors, the SUV peak is the most reliable parameter for [18F]FDG-PET/CT quantification, regardless of acquisition time. EJNMMI Research. https://doi.org/10.1186/s13550-016-0177-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.